Raymond James Financial Inc. Has $19.58 Million Stock Position in Halozyme Therapeutics, Inc. $HALO

Key Points

• Raymond James Financial Inc. has reduced its stake in Halozyme Therapeutics by 32.8%, now holding approximately $19.6 million worth of shares following a sale of 149,995 shares.
• Insider activity includes CEO Helen Torley selling 20,000 shares for over $1.27 million, decreasing her ownership by 2.65%.
• Analysts have mixed ratings on Halozyme, with four Buy, five Hold, and two Sell ratings, while the average target price stands at $67.11.

Raymond James Financial Inc. reduced its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 32.8% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 306,779 shares of the biopharmaceutical company's stock after selling 149,995 shares during the quarter. Raymond James Financial Inc. owned about 0.25% of Halozyme Therapeutics worth $19,576,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Penserra Capital Management LLC bought a new position in Halozyme Therapeutics during the 1st quarter valued at $125,000. Bessemer Group Inc. lifted its position in shares of Halozyme Therapeutics by 62.9% during the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 207 shares during the last quarter. D. E. Shaw & Co. Inc. lifted its position in shares of Halozyme Therapeutics by 171.2% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 831,414 shares of the biopharmaceutical company's stock valued at $39,750,000 after acquiring an additional 524,802 shares during the last quarter. Fifth Third Bancorp lifted its position in shares of Halozyme Therapeutics by 29.4% during the 1st quarter. Fifth Third Bancorp now owns 10,017 shares of the biopharmaceutical company's stock valued at $639,000 after acquiring an additional 2,276 shares during the last quarter. Finally, GAMMA Investing LLC lifted its position in shares of Halozyme Therapeutics by 199.0% during the 1st quarter. GAMMA Investing LLC now owns 2,802 shares of the biopharmaceutical company's stock valued at $179,000 after acquiring an additional 1,865 shares during the last quarter. 97.79% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. JPMorgan Chase & Co. increased their price objective on Halozyme Therapeutics from $60.00 to $63.00 and gave the company a "neutral" rating in a research report on Thursday, August 7th. HC Wainwright increased their price objective on Halozyme Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a research report on Wednesday, August 6th. Leerink Partnrs downgraded Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Tuesday, May 13th. The Goldman Sachs Group started coverage on Halozyme Therapeutics in a research report on Thursday, July 10th. They set a "neutral" rating and a $55.00 price objective for the company. Finally, Wells Fargo & Company raised their target price on Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a research report on Wednesday, May 7th. Four equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat.com, Halozyme Therapeutics has a consensus rating of "Hold" and a consensus target price of $67.11.

Insider Transactions at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $63.51, for a total transaction of $1,270,200.00. Following the completion of the sale, the chief executive officer owned 733,719 shares of the company's stock, valued at approximately $46,598,493.69. This trade represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 80,000 shares of company stock worth $4,532,600 over the last ninety days. 2.90% of the stock is currently owned by company insiders.

Halozyme Therapeutics Stock Up 0.5%

Shares of Halozyme Therapeutics stock traded up $0.34 during midday trading on Monday, hitting $73.15. The company's stock had a trading volume of 1,163,957 shares, compared to its average volume of 2,229,040. The firm has a market capitalization of $8.56 billion, a P/E ratio of 16.74, a PEG ratio of 0.42 and a beta of 1.19. The stock has a 50-day simple moving average of $60.68 and a 200-day simple moving average of $59.28. The company has a quick ratio of 7.01, a current ratio of 8.36 and a debt-to-equity ratio of 4.54. Halozyme Therapeutics, Inc. has a 1-year low of $42.01 and a 1-year high of $74.07.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, topping the consensus estimate of $1.23 by $0.31. The business had revenue of $325.72 million during the quarter, compared to analysts' expectations of $282.66 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.Halozyme Therapeutics's revenue was up 40.8% compared to the same quarter last year. During the same quarter last year, the firm posted $0.91 earnings per share. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. As a group, sell-side analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.